B
BioMarin Pharmaceutical Inc.
Profile managed by Bizz IdBioMarin
Estados Unidos
500+ employees
Description
Leading rare disease biotechnology company headquartered in San Rafael, CA. Pioneer in enzyme replacement therapies (ERT) with 6 approved products (orphan). Portfolio includes Naglazyme, Aldurazyme and Vimizim. In 2025 acquired Amicus Therapeutics for $4.8B and Inozyme for $270M.